8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2020

Viemed Healthcare, Inc.

(Exact name of registrant as specified in its charter)

(337) 504-3802

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 4, 2020, the board of directors (the “Board”) of Viemed Healthcare, Inc. (the “Company”), upon the recommendation of the Corporate Governance and Nominating Committee of the Board, increased the size of the Board from seven to eight individuals and appointed Sabrina Heltz to fill the vacancy created by the increase in size of the Board until her successor is duly elected and qualified at the next annual meeting of the shareholders or until her earlier resignation or removal. Ms. Heltz was also appointed to serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board (the “Board Committees”).

Ms. Heltz, in connection with her service on the Board and the Board Committees, was issued on the date of her appointment (i) $85,000 of restricted stock, with a vesting of one year, and (ii) a cash payment in the amount of $64,417, which amount represents a pro rata portion of cash compensation to be received as a Board member. There are no other arrangements or understandings between Ms. Heltz and any other persons pursuant to which she was selected as a director, and Ms. Heltz has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01.    Regulation FD Disclosure.

The Company also issued a press release on November 9, 2020 announcing the appointment of Ms. Heltz as an independent director. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.    Financial Statements and Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange of Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 9, 2020

Document

VIEMED HEALTHCARE ANNOUNCES NEW INDEPENDENT BOARD MEMBER

Lafayette, Louisiana (November 9, 2020) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that Sabrina Heltz has joined the Board of Directors as an independent director.

Ms. Heltz began her career at Blue Cross and Blue Shield of Louisiana (“BCBSLA”) as an actuary and earned her credentials as an Associate in the Society of Actuaries and a Member of the American Academy of Actuaries. During her time at BCBSLA, she ascended in her role and responsibilities, ultimately serving as SVP/Chief Actuary of the plan for five years. Her career then transitioned to managing other operational areas of BCBSLA, including its pharmacy benefits program, medical management program and provider reimbursement areas. She ended her 31 year career at BCBSLA as SVP overseeing the provider contracting and reimbursement programs for the plan, spearheading the advancement of the plan's data and analytics capabilities to enable value based reimbursement programs and innovative quality and care improvement programs. Following her career at BCBSLA, she served for four years at Ochsner Health Network as Chief Operations Officer and recently transitioned to an executive advisor, assisting the network in its strategy and operations to enable success in value based contracts offered by Medicare and commercial health plans.

Ms. Heltz brings to Viemed extensive healthcare leadership experience specifically related to healthcare systems and the private insurance sector.

“We are extremely excited to have Sabrina join our Board of Directors, as we are continuing to build out our service offering to more healthcare systems and innovative payor models,” said Casey Hoyt, Viemed's CEO. “Sabrina brings a wealth of experience to our outstanding and dedicated team, and I am confident that she will add a skillset to our Board that will enable us to continue to expand our service offerings. We are fortunate to have Sabrina, and her outstanding track record across decades of service, join our team and continue the passion of servicing chronically ill patients in the home.”

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod

Bristol Capital

905-326-1888

glen@bristolir.com

Todd Zehnder

Chief Operating Officer

Viemed Healthcare, Inc.

337-504-3802

investorinfo@viemed.com